LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.44

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.42

Máximo

0.44

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+59.57% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-9.5M 30M
Abertura anterior	0.44
Fecho anterior	0.44

Sentimento de Notícias

By Acuity

46%

54%

147 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.705 / 0.771 Suporte e Resistência

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de mai. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 de mai. de 2026, 22:52 UTC

Grandes Movimentos do Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 de mai. de 2026, 23:44 UTC

Ganhos

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 de mai. de 2026, 23:35 UTC

Conversa de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 de mai. de 2026, 23:15 UTC

Conversa de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 de mai. de 2026, 23:14 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 de mai. de 2026, 23:02 UTC

Conversa de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 22:27 UTC

Conversa de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 de mai. de 2026, 22:14 UTC

Conversa de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 de mai. de 2026, 22:10 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 de mai. de 2026, 22:00 UTC

Ganhos

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 de mai. de 2026, 21:38 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 de mai. de 2026, 21:27 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 de mai. de 2026, 21:20 UTC

Ganhos

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 de mai. de 2026, 21:19 UTC

Ganhos

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 de mai. de 2026, 21:18 UTC

Ganhos

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 de mai. de 2026, 21:16 UTC

Ganhos

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

59.57% parte superior

Previsão para 12 meses

Média 0.75 USD 59.57%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

All events are bearish.

Sentimento

By Acuity

147 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.